NVCT - Nuvectis Pharma Inc
9.33
-0.320 -3.430%
Share volume: 39,407
Last Updated: 03-11-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.16%
PREVIOUS CLOSE
CHG
CHG%
$9.65
-0.32
-0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-07-2024 | 08-06-2024 | 11-05-2024 | 02-25-2025 | 05-06-2025 | 11-04-2025 | 02-11-2026 | |
| Assets | ||||||||
| Total Assets | 19.714 M | 18.298 M | 17.307 M | 18.607 M | 30.148 M | 35.587 M | 31.709 M | |
| Current Assets | 19.714 M | 18.298 M | 17.307 M | 18.607 M | 30.148 M | 35.587 M | 31.709 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 250.000 K | 182.000 K | 138.000 K | 74.000 K | 284.000 K | 145.000 K | 75.000 K | |
| Short Term Investments | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 19.464 M | 18.116 M | 17.169 M | 18.533 M | 29.864 M | 35.442 M | 31.634 M | |
| Total Non-current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 19.714 M | 18.298 M | 17.307 M | 18.607 M | 30.148 M | 35.587 M | 31.709 M | |
| Total liabilities | 5.692 M | 5.770 M | 6.316 M | 8.894 M | 9.194 M | 11.577 M | 13.296 M | |
| Total current liabilities | 5.692 M | 5.770 M | 6.316 M | 8.894 M | 9.194 M | 11.577 M | 13.296 M | |
| Accounts Payable | 1.759 M | 1.846 M | 2.261 M | 2.498 M | 2.992 M | 6.439 M | 6.274 M | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 14.022 M | 12.528 M | 10.991 M | 9.713 M | 20.954 M | 24.010 M | 18.413 M | |
| Common stock | 72.438 M | 75.372 M | 77.988 M | 82.958 M | 99.531 M | 116.383 M | 118.100 M | |
| Retained earnings | -58.416 M | -62.844 M | -66.997 M | -73.245 M | -78.577 M | -92.373 M | -99.687 M |